Statin Therapy

Some in the medical community were initially skeptical of the first statin to win FDA approval, according to a history of the medication published in Heart Views. Now, 32 years later, research suggests it is patients who are reluctant to fully embrace statin use.

Use of statins as monotherapy or in combination with metformin appeared associated with lower mortality among men with high-risk prostate cancer, according to results of a retrospective study published in Cancer Medicine.

CV outcomes in high-risk patients with diabetes receiving statin therapy were strongly associated with baseline HbA1c levels, according to findings published in the Journal of the American Heart Association.

Some patients who initiated statin or antihypertensive medications made unfavorable lifestyle changes such as gaining weight and participating in less physical activity, according to a study published in the Journal of the American Heart Association.

Patients who adhered to alirocumab and background statin therapy did not experience any significant diminution in the treatment’s lipid-lowering efficacy after 3 years, according to a research letter published in the Journal of the American College of Cardiology.

There is now plentiful evidence that medical therapy benefits patients with peripheral artery disease, which is reflected in guidelines but not followed nearly enough, a speaker stated at the International Symposium on Endovascular Therapy.

A novel score to predict 10-year risk for incident CV events using patient-reported information was comparable to the atherosclerotic CVD risk score, according to a study published in the Journal of the American Heart Association.

The cornerstone of CV prevention is risk assessment because patients at higher risk for atherosclerotic events typically derive a higher absolute benefit from preventive therapies.

AstraZeneca announced that it will close the STRENGTH CV outcomes trial of omega-3 carboxylic acids in patients with mixed dyslipidemia at high risk for CVD.

The risk for major adverse CV events after recent ACS could be predicted by baseline lipoprotein(a) and corrected LDL levels and their reductions with alirocumab, according to an analysis of the ODYSSEY Outcomes trial published in the Journal of the American College of Cardiology.